BioCentury | Jul 2, 2012
Clinical News

HI-1640V: Preliminary Phase IIb data

...this month. Bioxyne also said it will consider out-licensing HI-164OV for other indications. In March, Probiomics Ltd....
BioCentury | Apr 2, 2012
Company News

Hunter Immunology, Probiomics deal

...the ASX on April 4 (see BioCentury, Jan. 2). Hunter Immunology Ltd. , Sydney, Australia Probiomics Ltd....
BioCentury | Jan 2, 2012
Company News

Hunter Immunology, Probiomics deal

...Hunter's board recommended that shareholders accept an October merger offer from probiotics company Probiomics. The stock...
...Hunter, an unlisted public company, at about A$29.7 million ($29.4 million). Details were not disclosed. Probiomics...
...June 30, 2011. The deal, which is subject to Probiomics shareholder approval as well as Probiomics...
BioCentury | Jul 18, 2011
Company News

Proquifin S.A. de C.V., Vanda sales and marketing update

Vanda granted Proquifin's Probiomed S.A. de C.V. pharmaceutical operating unit exclusive rights in Mexico to commercialize schizophrenia drug Fanapt iloperidone. Probiomed, which is responsible for gaining regulatory approval in Mexico, plans to submit a marketing...
BioCentury | May 16, 2005
Finance

Taking the ADR route

...Denmark BNY 12/23/02 Chemgenex OTC CXSFY Australia BNY 12/6/02 Roche OTC RHHBY Switzerland BNY 12/5/02 VRI Biomedical...
Items per page:
1 - 5 of 5
BioCentury | Jul 2, 2012
Clinical News

HI-1640V: Preliminary Phase IIb data

...this month. Bioxyne also said it will consider out-licensing HI-164OV for other indications. In March, Probiomics Ltd....
BioCentury | Apr 2, 2012
Company News

Hunter Immunology, Probiomics deal

...the ASX on April 4 (see BioCentury, Jan. 2). Hunter Immunology Ltd. , Sydney, Australia Probiomics Ltd....
BioCentury | Jan 2, 2012
Company News

Hunter Immunology, Probiomics deal

...Hunter's board recommended that shareholders accept an October merger offer from probiotics company Probiomics. The stock...
...Hunter, an unlisted public company, at about A$29.7 million ($29.4 million). Details were not disclosed. Probiomics...
...June 30, 2011. The deal, which is subject to Probiomics shareholder approval as well as Probiomics...
BioCentury | Jul 18, 2011
Company News

Proquifin S.A. de C.V., Vanda sales and marketing update

Vanda granted Proquifin's Probiomed S.A. de C.V. pharmaceutical operating unit exclusive rights in Mexico to commercialize schizophrenia drug Fanapt iloperidone. Probiomed, which is responsible for gaining regulatory approval in Mexico, plans to submit a marketing...
BioCentury | May 16, 2005
Finance

Taking the ADR route

...Denmark BNY 12/23/02 Chemgenex OTC CXSFY Australia BNY 12/6/02 Roche OTC RHHBY Switzerland BNY 12/5/02 VRI Biomedical...
Items per page:
1 - 5 of 5